Fresenius Medical Care stock hit by Barclays downgrade and lower target

Published on 11/09/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock faces a fresh warning from Barclays over reimbursement pressure and weak volume growth. The bank cut its target.

Barclays turns more cautious

Barclays lowered its rating on Fresenius Medical Care and reduced its price target.
The bank cited reimbursement pressure, weak volume growth and inflation as risks to earnings.
Barclays expects the 2027 operating outlook to remain under pressure as TDAPA support fades.

FMC, DE0005785802, Illustration mit AI erstellt.

Barclays has turned more cautious on Fresenius Medical Care after citing reimbursement pressure, weak volume growth and inflation as threats to earnings. The bank downgraded the dialysis group to underweight from equal weight and cut its price target to 35 euros from 44.50 euros, according to a report carried by Yahoo Finance.

New pressure on future earnings

The revised target reflects Barclays' view that adjusted operating profit could decline by an average of 3 percent a year between 2025 and 2028. For 2027, the bank forecasts adjusted operating profit of 1.85 billion euros and adjusted earnings per share of 3.61 euros, down from its earlier estimate of 4.49 euros.

Barclays expects the fading contribution from the U.S. TDAPA reimbursement program to weigh heavily on 2027 results. The bank estimates a 300 million to 350 million euro impact on operating income, including the loss of a benefit received in 2026 and additional pressure in the pharmaceuticals business.

Execution remains central

The bank also expects little to no U.S. volume growth in 2027, forecasting an increase of 0.2 percent after a decline of 0.9 percent in 2026. It linked the weak outlook to patient-referral and execution challenges, while identifying faster volume growth as an upside risk if the new management team improves patient inflows.

Fresenius Medical Care stock traded at 40.95 euros on Lang & Schwarz at 17:40 CET on Monday, November 9, 2026.